Measuring the dimension of invasive component in pT1 urothelial carcinoma in transurethral resection specimens can predict time to recurrence

Soloway, 1988, Intravesical therapy for bladder cancer, Urol Clin N Am, 15, 661, 10.1016/S0094-0143(21)01782-1

Hall, 2007, Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update, J Urol, 178, 2314, 10.1016/j.juro.2007.09.003

Nepple, 2009, The optimal management of T1 high-grade bladder cancer, Can Urol Assoc J, 3, S188, 10.5489/cuaj.1194

Flamm, 1982, Cystectomy or transurethral resection in the treatment of bladder carcinoma, Z Urol Nephrol, 75, 729

Sylvester, 2006, Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials, Eur Urol, 49, 465, 10.1016/j.eururo.2005.12.031

Mai, 2004, Histopathological and immunohistochemical study of papillary urothelial neoplasms of low malignant potential and grade associated with extensive invasive low-grade urothelial carcinoma, BJU Int, 94, 544, 10.1111/j.1464-4096.2004.04923.x

Pich, 2002, Proliferative activity is the most significant predictor of recurrence in noninvasive papillary urothelial neoplasms of low malignant potential and grade 1 papillary carcinomas of the bladder, Cancer, 95, 784, 10.1002/cncr.10733

Schulze, 2007, Retrospective analysis of transurethral resection, second-look resection, and long-term chemo-metaphylaxis for superficial bladder cancer: indications and efficacy of a differentiated approach, J Endourol, 21, 1533, 10.1089/end.2007.9866

Dalbagni G, Kaag M, Cronin A, Vora K, Bochner B, Donat SM, et al. Variability of treatment selection among surgeons for patients with cT1 urothelial carcinoma. BJU Int; 106, 1502-7.

Herr, 1990, The T1 bladder tumor, Semin Urol, 8, 254

Divrik RT, Sahin AF, Yildirim U, Altok M, Zorlu F. Impact of routine second transurethral resection on the long-term outcome of patients with newly diagnosed pT1 urothelial carcinoma with respect to recurrence, progression rate, and disease-specific survival: a prospective randomised clinical trial. Eur Urol; 58, 185-90.

Cho, 2009, Differences in tumor characteristics and prognosis in newly diagnosed Ta, T1 urothelial carcinoma of bladder according to patient age, Urology, 73, 828, 10.1016/j.urology.2008.10.038

Cheng, 1999, Predicting cancer progression in patients with stage T1 bladder carcinoma, J Clin Oncol, 17, 3182, 10.1200/JCO.1999.17.10.3182

Cheng, 2000, Predicting extravesical extension of bladder carcinoma: a novel method based on micrometer measurement of the depth of invasion in transurethral resection specimens, Urology, 55, 668, 10.1016/S0090-4295(99)00595-6

Bertz S, Denzinger S, Otto W, Wieland WF, Stoehr R, Hofstaedter F, Hartmann A. Substaging by estimating the size of invasive tumour can improve risk stratification in pT1 urothelial bladder cancer-evaluation of a large hospital-based single-centre series. Histopathology; 59, 722-32.

Brimo, 2013, Prognostic factors in T1 bladder urothelial carcinoma: the value of recording millimetric depth of invasion, diameter of invasive carcinoma, and muscularis mucosa invasion, Hum Pathol, 44, 95, 10.1016/j.humpath.2012.04.020

Lopez-Beltran, 2003, Stage pT1 bladder carcinoma: diagnostic criteria, pitfalls and prognostic significance, Pathology, 35, 484, 10.1080/00313020310001619127

van der Aa, 2005, A new system for substaging pT1 papillary bladder cancer: a prognostic evaluation, Hum Pathol, 36, 981, 10.1016/j.humpath.2005.06.017

Paner, 2007, Further characterization of the muscle layers and lamina propria of the urinary bladder by systematic histologic mapping: implications for pathologic staging of invasive urothelial carcinoma, Am J Surg Pathol, 31, 1420, 10.1097/PAS.0b013e3180588283

Cheng, 1999, Substaging of T1 bladder carcinoma based on the depth of invasion as measured by micrometer: a new proposal, Cancer, 86, 1035, 10.1002/(SICI)1097-0142(19990915)86:6<1035::AID-CNCR20>3.0.CO;2-D

Iida, 2009, Clinical outcome of high-grade non-muscle-invasive bladder cancer: a long-term single center experience, Int J Urol, 16, 287, 10.1111/j.1442-2042.2008.02239.x

Sakano S, Matsuyama H, Takai K, Yoshihiro S, Kamiryo Y, Shirataki S, Kaneda Y, Hashimoto O, Joko K, Suga A, Yamamoto M, Hayashida S, Baba Y, Aoki A. Risk group stratification to predict recurrence after transurethral resection in Japanese patients with stage Ta and T1 bladder tumours: validation study on the European Association of Urology guidelines. BJU Int 2011;107:1598-604.

Babjuk, 2012, EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update, Actas Urol Esp, 36, 389, 10.1016/j.acuroe.2011.12.007

Koga, 2004, A randomized controlled trial of short-term versus long-term prophylactic intravesical instillation chemotherapy for recurrence after transurethral resection of Ta/T1 transitional cell carcinoma of the bladder, J Urol, 171, 153, 10.1097/01.ju.0000100386.07370.0a

Nielsen, 2007, Recurrence-free survival after radical cystectomy of patients downstaged by transurethral resection, Urology, 70, 1091, 10.1016/j.urology.2007.08.044

Tahoun NS, Abdel Maksoud AM, Mohamed DB. Evaluation of the value of combined urine cytology and cystoscopy for follow-up of superficial transitional cell carcinoma of the urinary bladder. J Egypt Natl Canc Inst 201;22:105-11.